Valeant Pharma (VRX) Halts the Bloodletting Following Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Valeant Pharma (VRX) Halts the Bloodletting Following Conference Call
October 26, 2015 9:00 AM EDT
LAVAL, Quebec, Oct. 26, 2015 /PRNewswire/ --Â J. Michael Pearson, Chairman and Chief Executive Officer of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX), made the following statements on today's investor call.
Statement of J. Michael Pearson:
"We wanted to hold this call today because the company I've heard described in the press the past few days is not one that I recognize. It's not one that our board of directors recognizes. And it's certainly not one that reflects the... More
October 26, 2015 6:15 AM EDT
VALEANT TO HOLD INVESTOR CONFERENCE CALL AT 8:00 AM ET
LAVAL, Quebec, Oct. 26, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that its Audit and Risk Committee and the full Board of Directors have reviewed the company's accounting for its Philidor arrangement and have confirmed the appropriateness of the company's related revenue recognition and accounting treatment.
Based on its review conducted to date, Valeant also believes that the company is in compliance with applicable law. In... More
